Brilliant Violet 421™ anti-mouse CD45 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse thymus or spleen

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation³, complement-dependent cytotoxicity^1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)^4,6, Western blotting⁷, and spatial biology (IBEX)^10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)

1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
8. Liu F, et al. 2012. Blood. 119:3295. PubMed
9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
2. Naito H, et al. 2020. Nature Protocols. 15(3):1066-1081. PubMed
3. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
4. Balood M, et al. 2022. Nature. 611:405. PubMed
5. Millar FR, et al. 2022. Cell Rep. 41:111596. PubMed
6. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
7. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
8. Pariury H, et al. 2023. Haematologica. :. PubMed
9. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
10. Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed
11. Hentzschel F, et al. 2022. Sci Adv. 8:eabm7348. PubMed
12. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
13. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
14. Schlecht A, et al. 2021. Int J Mol Sci. 22:. PubMed
15. Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed
16. Shiroshita K, et al. 2022. Cell Rep Methods. 2:100354. PubMed
17. Gómez-Salinero JM, et al. 2022. Nat Cardiovasc Res. 1:882. PubMed
18. Ando M, et al. 2021. Cancer Res Commun. 1:41. PubMed
19. Takimoto Y, et al. 2023. iScience. 26:106220. PubMed
20. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
21. Willows JW, et al. 2023. iScience. 26:106189. PubMed
22. Chung KJ, et al. 2023. Int J Mol Sci. 24:. PubMed
23. Cui W, et al. 2023. J Exp Med. 220:. PubMed
24. Ishida K, et al. 2023. Front Immunol. 14:1111729. PubMed
25. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
26. Cullis J, et al. 2017. Cancer Immunol Res. 5:182. PubMed
27. Ulland TK et al. 2017. Cell. 170(4):649-663 . PubMed
28. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
29. Galán-Díez M, et al. 2022. Cancer Discov. . PubMed
30. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
31. Deng J, et al. 2021. JCI Insight. 6:146133. PubMed
32. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
33. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
34. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
35. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
36. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
37. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
38. Karlsson J, et al. 2021. Adv Funct Mater. 31:. PubMed
39. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
40. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
41. Song WM, et al. 2018. J Exp Med. 215:745. PubMed
42. Shmeleva EV, et al. 2019. Front Immunol. 10:1780. PubMed
43. Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed
44. Cui Z, et al. 2022. Bone Res. 10:58. PubMed
45. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
46. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
47. Crncec I, et al. 2018. Mol Oncol. 12:514. PubMed
48. Kobayashi H, et al. 2020. STAR Protoc. 1:100078. PubMed
49. Schlecht A, et al. 2021. Front Cell Dev Biol. 8:618598. PubMed
50. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
51. Bell BJ, et al. 2022. Brain Behav Immun Health. 23:100478. PubMed
52. Helm M, et al. 2022. Life (Basel). 12:. PubMed
53. Nishiga Y, et al. 2022. Nat Cancer. 3:1351. PubMed
54. Suter EC, et al. 2021. Cell Reports. 36(8):109587. PubMed
55. Mittal S, et al. 2016. Stem Cell Reports. 7:583-590. PubMed
56. Saika A, et al. 2020. FASEB Bioadv. 2:59. PubMed
57. Chu C, et al. 2016. Dis Model Mech. 9: 473-481. PubMed
58. Hagan AS, et al. 2020. Development. 147:00:00. PubMed
59. Kramann R, et al. 2018. JCI Insight. 3. PubMed
60. Parlet CP, et al. 2019. Cell Rep. 27:187. PubMed
61. Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed
62. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
63. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
64. Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed
65. Li J, et al. 2020. Elife. 9:00. PubMed
66. Li Q, et al. 2019. Front Cell Neurosci. 12:520. PubMed
67. Mamedov MR, et al. 2018. Immunity. 48:350. PubMed
68. Agalave NM, et al. 2021. Front Immunol. 12:642420. PubMed
69. Katara GK, et al. 2020. Mol Oncol. 0.729861111. PubMed
70. de Lucía Finkel P, et al. 2021. Sci Rep. 11:12233. PubMed
71. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
72. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
73. Boeck M, et al. 2020. Glia. 1859:68. PubMed
74. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
75. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
76. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
77. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
78. Bersini S, et al. 2020. Life Sci Alliance. 3:e201900623. PubMed
79. Durré T, et al. 2018. Nat Commun. 9:5178. PubMed
80. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
81. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
82. Ma Z, et al. 2022. Methods Mol Biol. 2471:49. PubMed
83. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
84. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
85. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
86. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
87. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
88. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
89. Zhang P, et al. 2021. J Neuroinflammation. 18:215. PubMed
90. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
91. Wieghofer P, et al. 2021. EMBO J. 40:e105123. PubMed
92. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
93. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
94. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
95. Wakabayashi T et al. 2018. Cell stem cell. 22(3):384-397 . PubMed
96. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
97. Zheng X, et al. 2020. Int J Cancer. 146:1730. PubMed
98. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
99. Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed
100. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
101. Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed
102. Meng Michelle Xu et al. 2017. Immunity. 47(2):363-373 . PubMed
103. Süß P, et al. 2020. Cell Reports. 30(12):4082-4095. PubMed
104. Ombrato L, et al. 2021. Nat Protoc. 16:872. PubMed
105. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
106. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
107. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
108. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
109. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
110. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
111. Hu B, et al. 2020. J Clin Invest. 130:3483. PubMed
112. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
113. Nishimura T, et al. 2020. Cell Stem Cell. 28(1):141-149.e3. PubMed
114. Usui-Ouchi A, et al. 2020. Proc Natl Acad Sci U S A. 28297:117. PubMed
115. Boddupalli CS, et al. 2022. Elife. 11:. PubMed
116. Palma A, et al. 2022. Front Cell Dev Biol. 10:841548. PubMed
117. Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
118. Zheng H, et al. 2021. Frontiers in Immunology. 12:645100. PubMed
119. Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed
120. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed

RRID

AB_10899570 (BioLegend Cat. No. 103133)
AB_2562559 (BioLegend Cat. No. 103134)

Antigen Details

Structure

Protein tyrosine phosphatase (PTP) family, 180-240 kD

Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function

Phosphatase, T and B cell activation

Ligand/Receptor

Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1

Cell Type

B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs

Biology Area

Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID

19264 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

CD45

Specificity Alt (DOES NOT SHOW ON TDS):

CD45

App Abbreviation (DOES NOT SHOW ON TDS):

FC,SB

UniProt

View information about CD45 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

Certificate of Analysis